You may not have heard of contract manufacturing organizations before now, but they’ve certainly influenced your life. Most notably in recent months, these organizations have been crucial in helping manufacture the hundreds of millions of vaccine doses necessary to help dramatically decrease the spread of the COVID-19 pandemic, saving quite likely millions of lives.
Contract manufacturing organizations work closely with biotech firms and pharmaceutical companies of all kinds, helping expand their production and manufacturing abilities when it comes to research and development as well as the mass production of treatments. They also offer services that include biosafety testing, packaging, and more.
At the forefront of contract manufacturing organizations doing important work worldwide is Samsung Biologics, a global leader with a range of exciting announcements in 2021.
Samsung Biologics: Recent Performance & News
Want to get up-to-date on what Samsung Biologics has been achieving and working towards in recent months? Here are a few of their most recent updates, straight from their official newsroom and confirmed media reports.
Partnerships with Industry Leaders Samsung Biologics recently announced partnership with Moderna, the drug manufacturer most recently known for their COVID-19 mRNA vaccine. Samsung Biologics will serve in the role of contract manufacturing organization to help expand what the company is capable of when it comes to completing and manufacturing their drug products for worldwide use.
Expanding Capabilities for mRNA Vaccine Manufacturing
Samsung Biologics also announced that they’ll be adding mRNA vaccine drug substance manufacturing suite to one of their existing facilities, making them more capable than ever when it comes to providing vaccine production for a range of clients— including the potential to serve those developing other mRNA vaccines on a larger scale.
Development of Record-Breaking Manufacturing Plant
Samsung Biologics is also set to shatter a longstanding record, when their soon-to-be-completed fourth manufacturing plant will hold the industry’s largest manufacturing capacity at a single-site on the planet. One primary area of focus in the plant’s development has been the modernization of processes that will provide more efficiency, quality control, and better client service.
“In automating our facilities,” said James Choi, SVP, Chief Information & Marketing Officer, and Head of Investor Relations,
What’s Next for Samsung Biologics in their Role as a Contract Manufacturing Organization?
“We will look beyond the next decade,” CEO John Rim said, “and evolve as the global top-tier biopharmaceutical company by securing future growth engines with continued investment and expansion in capacity, portfolio, and global footprint. With a steadfast vision and unrelenting drive to achieve better life for all, we embrace responsibility, expertise, and pride in our work, and will continue on our noble mission to enable improved accessibility of biomedicines and consequently the quality of life for people around the globe.”